导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.97% | 1416/4773 |
| 近一周 | -0.19% | 581/5458 |
| 近一月 | 1.67% | 467/5421 |
| 近一季 | 0.59% | 923/5205 |
| 近半年 | -3.55% | 2421/4920 |
| 近一年 | 3.90% | 1976/4361 |
| 近两年 | 25.79% | 2503/2954 |
| 近三年 | 17.99% | 1548/2253 |
| 成立以来 | 210.02% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.89% 638/4961 |
-10.29% 4084/5312 |
- - |
- - |
| 2025 | 2.63% 3172/4813 |
-2.84% 2995/3635 |
2.25% 1717/4076 |
2.36% 3803/4524 |
0.93% 1653/4813 |
| 2024 | 16.31% 827/3463 |
7.69% 232/2808 |
1.86% 435/3014 |
8.14% 2767/3129 |
-1.95% 1897/3463 |
| 2023 | 4.27% 235/2656 |
4.55% 920/2280 |
0.59% 306/2385 |
3.74% 170/2515 |
-4.43% 1030/2655 |
| 2022 | -2.27% 54/2207 |
1.44% 101/1919 |
-1.14% 1680/2016 |
-2.36% 35/2113 |
-0.19% 1572/2208 |
| 2021 | 17.16% 244/1822 |
4.99% 125/1255 |
8.53% 616/1330 |
3.91% 393/1466 |
-1.05% 1304/1822 |
| 2020 | 8.93% 850/1250 |
-10.05% 742/1028 |
5.39% 882/1067 |
9.79% 620/1164 |
4.66% 832/1184 |
| 2019 | 19.54% 675/1092 |
22.06% 579/754 |
-4.56% 430/804 |
-2.43% 700/850 |
5.16% 742/918 |
| 2018 | -13.79% 91/834 |
- - |
- - |
- - |
-6.40% 44/691 |
| 2017 | 26.26% 103/714 |
- - |
- - |
- - |
- - |
| 2016 | -4.49% 158/605 |
- - |
- - |
- - |
- - |
| 2015 | 25.29% 92/575 |
- - |
- - |
- - |
- - |
| 2014 | 51.59% 71/237 |
- - |
- - |
- - |
- - |
| 2013 | -7.54% 123/186 |
- - |
- - |
- - |
- - |
| 2012 | 7.20% 65/140 |
- - |
- - |
- - |
- - |
| 2011 | -22.05% 48/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 大成中证红利指数A VS. 长安沪深300非周期A(740101) |